sucralfate NDC 0378-9205

NDC codes

FDA NDC Directory

Product NDC (as listed)0378-9205Labeler and product segments. Claims need a package NDC.

Product NDC at billing width00378-9205Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
0378-9205-35	00378920535	420 mL in 1 BOTTLE, PLASTIC (0378-9205-35)Marketed from Sep 22, 2022

How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): sucralfate
Generic name (nonproprietary): sucralfate
Active ingredients: Sucralfate — 1 g/10mL
Dosage form: Suspension
Route: Oral
Labeler: Mylan Pharmaceuticals Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 212913
Marketing start: Sep 22, 2022
Marketing end: Sep 30, 2026
Other FDA classes: Organometallic Compounds (Chemical structure)
Identifiers: Product ID 0378-9205_4db0204a-d28c-4e14-9b77-6105356373e2SPL ID 4db0204a-d28c-4e14-9b77-6105356373e2SPL set ID 1e781cc0-24ec-4028-8262-dcef9873ea1fRxCUI 313123UNII XX73205DH5
Pharmacologic class: Aluminum Complex

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N400378920535 followed by a unit qualifier and the quantity

Package 00378-9205-35. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jan 14, 2020.

Indications (excerpt from the label)

INDICATIONS AND USAGE Sucralfate oral suspension is indicated in the short-term (up to 8 weeks) treatment of active duodenal ulcer.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)